There is NO safe level of lead in the blood of a child. Exposure to lead can seriously harm a child’s health and cause well-documented adverse effects such as:

- Damage to the brain and nervous system
- Slowed growth and development
- Learning and behavior problems and underperformance in school
- Lower IQ and decreased ability to pay attention
- Hearing and speech problems

Lead is particularly dangerous because once in a person’s system, it is distributed throughout the body, causing harm wherever it lands. In the bloodstream, it can damage red blood cells and limit their ability to carry oxygen to organs and tissues, causing anemia. Most lead ends up in the bone where it interferes with the production of red blood cells and the absorption of calcium. The effects of long-term lead toxicity include damage to the nervous system, kidneys, and hearing, poor muscle coordination, and decreased bone and muscle growth.

The American Academy of Pediatrics recommends:

- Physicians continue to provide anticipatory guidance to parents in an effort to prevent lead exposure
- Pediatricians should increase their efforts to assess children at risk for lead exposure to find those with elevated blood lead levels (EBLLs)

Populations at higher risk of lead exposure include:

- Children from low-income households
- Immigrant and refugee children from less developed countries
- Some African American children, and those from other races and ethnicities, due to poor housing stock
- Those living in housing built before 1978
- Children younger than age 6 (hand to mouth activity)

However, children from all races, ethnicities and socioeconomic backgrounds can be at risk of exposure.

All homes built prior to 1978 have a risk for lead exposure, but homes built before 1950 carry a greater risk due to a higher content of lead used in paint before that time. Age and condition of housing, not geographic location, are the best predictors for the presence of hazards related to lead-based paint. Besides lead-based paint, secondary sources of lead continue to emerge (e.g., children’s jewelry, imported herbal supplements, cosmetics, and food products) and are not limited to high-risk populations.

Children Enrolled in Medicaid: Indiana statute requires that ALL children enrolled in Medicaid are to receive a blood lead level test at 12 and 24 months of age; ANY child enrolled in Medicaid between 36 and 72 months with no record of a previous blood lead test must also be tested.

Additional testing should be strongly considered if children:

- Live in a house built before 1978 or a home that was recently repaired or renovated.
- Are enrolled in Women, Infant and Children Supplemental Nutrition Program (WIC) or Head Start.
- Have any of the risk factors in the Verbal Risk Assessment (below).
- Are adopted outside the United States, in foster care, or are immigrants.
- Have a known history of lead exposure after the age of 2 years old.
- Have a sibling or a playmate with lead toxicity.
- Have parents who request testing.
- Live near a lead-emitting facility.
- Are exhibiting neurodevelopmental disabilities or conditions such as autism, attention-deficit/hyperactivity disorder, and learning delays.
- Have a history of ingested non-food items (e.g. jewelry, batteries, toys, etc.) or exhibit pica behavior.
• **Testing Refugee Populations:** CDC recommends that all refugee children 0-16 years of age should be evaluated for lead exposure with a blood lead test upon entry into the United States. Follow-up blood lead testing, 3-6 months after initial testing, should be provided to all refugee infants and children ≤6 years of age, regardless of initial screening result. Children and adolescents 7-16 years of age who had blood lead levels ≥3.5 µg/dL, and any child older than 7 years of age who has a risk factor (e.g., sibling with blood lead level ≥3.5 µg/dL) should also receive follow-up testing 3-6 months after initial testing. All pregnant and lactating women and girls should be tested. All newly arrived pregnant or breastfeeding women should be prescribed a prenatal or multivitamin with adequate iron and calcium. Referral to a healthcare provider with expertise in high-risk lead exposure treatment and management may be indicated for EBLLs.

• It is recommended that clinicians **assess all children** for the risk of lead exposure from ages 6 months to 6 years at **every well child visit**.

### Verbal Risk Assessment:

The **Verbal Risk Assessment** helps health care providers assess a child’s potential level of risk of exposure to lead hazards. It also provides health care providers an opportunity to educate families about lead hazards. **If the answer to any question on the Verbal Risk Assessment is “Yes” or “I don’t know,” then:**

- Test the child for lead toxicity at that time
- Test the child at least annually or if any other risk factor exists. Continue to test until the child turns 6 years old or responses to the assessment change.
- Provide lead toxicity prevention education

*Completion of the assessment does not meet the Medicaid testing requirement.*

<table>
<thead>
<tr>
<th>In the past year, has your child lived in, near, or regularly visited:</th>
<th>Yes</th>
<th>No</th>
<th>I don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>A house built before 1978 that has peeling, chipping, or flaking paint?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A house built before 1978 that has been remodeled within the past 6 months?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A sibling, cousin, or friend who has been diagnosed or treated for lead toxicity?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A factory or industrial plant or mine?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico, India, Middle East, Central America, South America, Africa, or Asia?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>In the past year, has your child been around adults who:</th>
<th>Yes</th>
<th>No</th>
<th>I don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Have a job that causes them to have frequent contact with lead (e.g. plumbers, construction, auto repair, metal/battery recycling, welders)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Have a hobby that causes them to have frequent contact with lead (e.g. hunt, fish, reload bullets, refinish furniture, work with stained glass, jewelry making)?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>In the past year, has your child consumed:</th>
<th>Yes</th>
<th>No</th>
<th>I don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food or beverages from ceramic cookware/dishware or imported pottery?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food or candy with spices imported or brought in from another country (such as turmeric)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ayurvedic medicines or home remedies (such as Azarcon, Greta)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dirt or non-food items regularly (more than the typical baby mouthing behavior)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cosmetics imported or brought from another country (such as Thanaka, Kohl)?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**General medical evaluation and testing recommendations:**

- Perform routine physical and history and developmental assessment. Evaluate achievement of, or regression from, milestones, particularly in psychosocial and language domains.
- Assess nutrition and risk for iron deficiency.
- Evaluate for lead exposure risks.
- Initial test may be a capillary or venous test. Children with identified risk factors should be retested with a venous sample.

**General clinical management recommendations:**

- Report the blood lead result to IDOH.
- Discuss result with family and counsel on any identified risk factors.
- Provide prevention education (i.e., lead sources, reducing/eliminating strategies, health education, etc.).
- Counsel on nutrition and healthy eating, focusing on iron, calcium, and Vitamin C intake.
- Communicate patient management information with local health department.
- Consider referral to Supplemental Nutrition Program for Women, Infants, and Children.

### Medical Evaluation and Testing Recommendations

<table>
<thead>
<tr>
<th>BLL &lt; 3.5 µg/dL</th>
<th>Clinical Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>General medical evaluation &amp; testing recommendations (given above)</td>
<td>General clinical management recommendations (given above)</td>
</tr>
<tr>
<td><strong>Who to test?</strong></td>
<td>- When reviewing lab results with family, for reference, the geometric mean blood lead level for children 1-5 years old is less than 2 µg/dL.</td>
</tr>
<tr>
<td>- Medicaid recipients at 12 and 24 months, or any time before 6 years old if not previously screened.</td>
<td>Chelation is NOT recommended in this blood lead level range.</td>
</tr>
<tr>
<td>- Children in homes built before 1978 or with other risk factors</td>
<td></td>
</tr>
<tr>
<td>- Children at the request of their parents/guardians.</td>
<td></td>
</tr>
<tr>
<td><strong>Monitor BLLs:</strong></td>
<td></td>
</tr>
<tr>
<td>- Retest of BLL done no later than 12 months.</td>
<td></td>
</tr>
</tbody>
</table>

### BLL 3.5-4.9 µg/dL

<table>
<thead>
<tr>
<th>General medical evaluation &amp; testing recommendations (given above), PLUS:</th>
<th>General clinical management recommendations (given above), PLUS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Note the child’s environmental history. Identify potential sources of exposure and provide preliminary advice on reducing/eliminating them.</td>
<td>- Assess the child’s environmental risk factors, eating habits, housing, and family’s social service needs.</td>
</tr>
<tr>
<td>- Ensure iron sufficiency with laboratory testing and treatment per Pediatric Environmental Health Specialty Unit (PEHSU) and American Academy of Pediatrics guidelines.</td>
<td>- Test for iron sufficiency. Consider starting a multivitamin tablet with iron.</td>
</tr>
<tr>
<td>- Perform structured developmental screening evaluations at periodic health visits to ensure appropriate developmental milestones are being met as lead effects may manifest over years.</td>
<td>- Test siblings, other children &lt;6 years old, and household contacts, especially pregnant and lactating women.</td>
</tr>
<tr>
<td>- Evaluate risk to household contacts such as siblings and pregnant/lactating women in the home.</td>
<td>- Include primary/secondary residence and child care facility as part of the investigation.</td>
</tr>
<tr>
<td><strong>Monitor BLLs:</strong></td>
<td>Chelation is NOT recommended in this BLL range.</td>
</tr>
<tr>
<td>- Confirmatory BLL draw within 3 months of original may be done within shorter time period to ensure blood lead level is not rising. Venous test preferred, capillary acceptable</td>
<td></td>
</tr>
<tr>
<td>- Retest of BLLs, done no later than 3 months.</td>
<td></td>
</tr>
<tr>
<td>- If retest result is in another range, follow up as for that range.</td>
<td></td>
</tr>
<tr>
<td>- If BLLs are stable or decreasing, monitor initially with venous BLLs every 3 months and thereafter based on venous BLL trend. If retest result is in another range, follow-up or retest as for that range.</td>
<td></td>
</tr>
</tbody>
</table>
## Childhood Blood Lead Medical Management Guidelines for Providers in Indiana

### BLL 5-14.9 µg/dL

**General medical evaluation & testing recommendations (given above), PLUS:**
- Note the child’s environmental history. Identify potential sources of exposure and provide preliminary advice on reducing/eliminating them.
- Ensure iron and calcium sufficiency with laboratory testing and treatment per Pediatric Environmental Health Specialty Unit (PEHSU) and American Academy of Pediatrics guidelines.
- Perform structured developmental screening evaluations at periodic health visits as lead effects may manifest over years.
- Evaluate risk to household contacts such as siblings and pregnant/lactating women in the home.

**Monitor BLLs:**
- Confirmatory BLL draw within 1-3 months of original. Venous test preferred, capillary acceptable
- Retest thereafter within 3 months until BLL declines
- If retest result is in another range, follow up as for that range.
- If BLLs are stable or decreasing, monitor initially with venous BLLs based on venous BLL trend. If retest result is in another range, follow-up or retest as for that range.

### BLL 15-19.9 µg/dL

**General clinical management recommendations (given above):**
- Clinical management as listed above

**Monitor BLLs:**
- Confirmatory BLL draw within 1 month of original. Venous test preferred, capillary acceptable
- Retest thereafter within 2 months until BLL declines
- If retest result is in another range, follow up as for that range.
- If BLLs are stable or decreasing, monitor initially with venous BLLs based on venous BLL trend. If retest result is in another range, follow-up or retest as for that range.

### BLL 20-44.9 µg/dL

**General medical evaluation & testing recommendations, PLUS:**
- Complete diagnostic evaluation, history and physical exam with neurodevelopmental assessment.

**Monitor BLLs:**
- Confirmatory BLL draw within 1 month. Venous test preferred, capillary acceptable
- Retest BLL: 20-29.9 µg/dL-within 1 month, BLL 30-44.9 µg/dL-within 2 weeks, to ensure BLL is not rising.
- Monitor monthly and afterward based on the BLL trend. If retest result is in another range, follow up as for that range.

### BLL 45-69.9 µg/dL (Urgent Medical Situation)

**General medical evaluation & testing recommendations, PLUS:**
- Any treatment for BLLs in this range and greater should be done in consultation with an expert. Contact IN Poison Control (1-800-222-1222) or Region 5 PEHSU (1-866-967-7337) for guidance regarding

**General clinical management recommendations, PLUS:**
- Additional evaluation such as abdominal x-ray should be considered based on environmental investigation and history (e.g. pica for paint chips, mouthing behaviors, etc.) Gut decontamination may be considered if leaded foreign bodies visualized on x-ray.
- Nutrition consult

Chelation is NOT recommended in this BLL range.

### BLL >69.9 µg/dL

**General medical evaluation & testing recommendations, PLUS:**
- Any treatment for BLLs in this range and greater should be done in consultation with an expert. Contact IN Poison Control (1-800-222-1222) or Region 5 PEHSU (1-866-967-7337) for guidance regarding

**General clinical management recommendations, PLUS:**
- Evaluate whether hospitalization is needed to reduce lead exposure (Managed with assistance of experienced provider).
- Notify LHD if admitted or chelation administered.
chelation, diagnostic tests, questions, etc.
   • Medical evaluation with diagnostic evaluation.
     • Can be done in an outpatient setting for most patients.
     • Patients with concerning symptoms (encephalopathy, ataxia, seizures, etc.) should be evaluated at a hospital.

Monitor BLLs:
   • Confirmatory BLL draw within 24 hours.
   • Consider reconfirming BLL, even for venous results.
   • Retesting dependent on BLL range. Retest, venous only, 1 month after chelation therapy is completed.
   • If confirmed in this range, monitor BLLs during chelation.
   • Retest every 2 to 4 weeks (or more based on most recent BLLs).
   • Modify treatment guidelines if BLL remains elevated.
   • Monitor frequently until BLL declines.

Chelation therapy:
   • Consult with a provider (e.g. Indiana Poison Center 1-800-222-1222, PEHSU) experienced in managing chelation therapy.
   • Chelation may be conducted at child’s home if no lead hazards are present in the home. Active lead exposure should be stopped prior to administering chelation therapy. If hazard is present in the home, removing the child from that exposure should be a priority and occur as soon as possible. Alternative housing should be sought if needed to stop exposure and allow chelation to safely be provided in a patient’s home. If no alternative housing can be found and/or if concerns exist regarding medical compliance, then hospitalization can be considered.
   • Consider bowel decontamination as an adjunct to chelation if abdominal X-ray indicates enteral lead is present.
   • Succimer can be prescribed.
   • A minimum of two weeks between courses is recommended, unless more prompt treatment is indicated.
   • Discontinue iron supplements.
   • Monitor for anemia and neutropenia.

Post-Chelation Therapy Guidelines:
   • Repeat venous lead test in 1 to 3 weeks after hospital discharge.
   • Repeat venous lead test every two weeks for 6 to 8 weeks after hospital discharge.
   • Monitor lead level closely for 4 to 6 months after chelation. If the lead level “rebounds” to pre-treatment levels, consider repeat chelation therapy.
   • Minimum of two-week intervals is needed between chelation courses.

BLL ≥ 70 µg /dL (Medical Emergency)

General medical evaluation & testing recommendations:

Monitor BLLs:
   • Confirmatory BLL draw done immediately, emergency lab test, considered Medical Emergency. Venous test is preferred.
   • Retesting dependent on BLL range. Retest, venous only, 1 month after chelation therapy is completed
   • Retest within 1 week to 1 month to ensure BLL is not rising.
   • Monitor monthly and afterward based on the BLL trend. If retest result is in another range, follow up as for that range.
   • Any treatment for BLLs in this range should be done in consultation with an expert.
   • Refer to CDC and American Academy of Pediatrics recommendations related to chelation management.

General clinical management recommendations, PLUS:

Follow chelation therapy and post-chelation therapy guidelines listed above.

Resources:
1. CDC: https://www.cdc.gov/nceh/lead/
2. Environmental Health Specialty Units (PEHSUs): https://childrensenviro.uic.edu/
3. AAPs Bright Futures Guidelines: https://brightfutures.aap.org/Pages/default.aspx
4. Indiana Department of Health, Lead and Healthy Homes Division: https://www.in.gov/health/lead-and-healthy-homes-division/